Physician profile
Mandi E Bohlen
NPI 1144698580
$1,539.15
in general payments reported to CMS, 2019-2025
25 companies · $545 in 2025
The $545 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $190 · 2023: $116 · 2024: $248 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $199.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $188.72 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $126.07 | 2021-2025 | Airsupra, Breztri |
| Dexcom, INC. | $125.66 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $103.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.93 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $97.28 | 2021-2025 | Veozah |
| Abbvie INC. | $69.02 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $68.52 | 2021-2022 | |
| Glaxosmithkline, LLC. | $65.25 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $57.33 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.52 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $41.18 | 2021-2022 | |
| Esperion Therapeutics, INC. | $34.04 | 2021-2022 | |
| Horizon Therapeutics Plc | $30.43 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $25.54 | 2025 | Zilbrysq |
| Abbott Laboratories | $24.96 | 2025 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $24.54 | 2022 | |
| Amarin Pharma, INC. | $18.30 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.85 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.59 | 2024 | |
| Lundbeck LLC | $16.53 | 2025 | Rexulti |
| Exact Sciences Corporation | $15.31 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $14.47 | 2023 | Yupelri |
| Boston Scientific Corporation | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandi Bohlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.